{"id":"fosnetupitant-palonosetron","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":{"setId":"8e47618e-af46-4d82-94e8-1507c042252d","title":"AKYNZEO (NETUPITANT AND PALONOSETRON) CAPSULE AKYNZEO (FOSNETUPITANT AND PALONOSETRON) INJECTION [HELSINN THERAPEUTICS (U.S.), INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fosnetupitant blocks neurokinin-1 (NK1) receptors, which are involved in the delayed phase of CINV, while palonosetron blocks serotonin 5-HT3 receptors, which mediate the acute phase of CINV. This dual-mechanism combination provides enhanced antiemetic coverage across both acute and delayed phases of chemotherapy-induced nausea and vomiting.","oneSentence":"Fosnetupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist that together prevent chemotherapy-induced nausea and vomiting (CINV) by blocking two distinct pathways in the chemoreceptor trigger zone and gastrointestinal tract.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:00.986Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT06904235","phase":"PHASE2","title":"Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)","status":"RECRUITING","sponsor":"Helsinn Healthcare SA","startDate":"2025-07-07","conditions":"Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy","enrollment":95},{"nctId":"NCT06840769","phase":"PHASE1","title":"A Clinical Trial to Assess Safety and Pharmacokinetics of Fosnetupitant 235 mg and Metabolites in Healthy Volunteers","status":"TERMINATED","sponsor":"Helsinn Healthcare SA","startDate":"2023-06-17","conditions":"Healthy Volunteers","enrollment":50},{"nctId":"NCT03403712","phase":"PHASE3","title":"A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2018-03-16","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":404}],"_emaApprovals":[],"_faersSignals":[{"count":11,"reaction":"DEATH"},{"count":4,"reaction":"DYSPNOEA"},{"count":3,"reaction":"COUGH"},{"count":2,"reaction":"BACK PAIN"},{"count":2,"reaction":"COLD SWEAT"},{"count":2,"reaction":"DISEASE PROGRESSION"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"FLUSHING"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"OFF LABEL USE"}],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IV NEPA FDC"],"phase":"marketed","status":"active","brandName":"fosnetupitant/ palonosetron","genericName":"fosnetupitant/ palonosetron","companyName":"Helsinn Healthcare SA","companyId":"helsinn-healthcare-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosnetupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist that together prevent chemotherapy-induced nausea and vomiting (CINV) by blocking two distinct pathways in the chemoreceptor trigger zone and gastrointestinal tract. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}